Sana Biotechnology, Inc. Short-term Lease, Cost
Sana Biotechnology, Inc. (SANA) reported Short-term Lease, Cost of $624.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShortTermLeaseCost · last filed 2026-08-10
- Sana Biotechnology, Inc. short-term lease, cost for the quarter ending 2026-06-30 was $624.00K, a 32.03% decline year-over-year.
- Sana Biotechnology, Inc. short-term lease, cost for the quarter ending 2026-03-31 was $715.00K, a 32.74% decline year-over-year.
- Sana Biotechnology, Inc. short-term lease, cost for the quarter ending 2025-12-31 was $749.00K, a 25.84% decline year-over-year.
- Sana Biotechnology, Inc. short-term lease, cost for the quarter ending 2025-09-30 was $846.00K, a 23.65% decline year-over-year.
- Sana Biotechnology, Inc. short-term lease, cost for fiscal 2025 was $3.58M, a 23.41% decline from fiscal 2024.
- Sana Biotechnology, Inc. short-term lease, cost for fiscal 2024 was $4.67M.
- Sana Biotechnology, Inc. short-term lease, cost for fiscal 2021 was $512.00K, a 72.85% decline from fiscal 2020.
- Sana Biotechnology, Inc. short-term lease, cost for fiscal 2020 was $1.89M, a 49.16% decline from fiscal 2019.
| Period end | Short-term Lease, Cost 3 month | Short-term Lease, Cost 6 month | Short-term Lease, Cost 9 month | Short-term Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $624.00K 10-Q · filed 2026-08-10 | $1.34M 10-Q · filed 2026-08-10 | $2.09M derived: sum of 3 quarters · filed 2026-08-10 | $2.93M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $715.00K 10-Q · filed 2026-05-11 | $1.46M derived: sum of 2 quarters · filed 2026-05-11 | $2.31M derived: sum of 3 quarters · filed 2026-05-11 | $3.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $749.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.59M derived: sum of 2 quarters · filed 2026-03-03 | $2.51M derived: sum of 3 quarters · filed 2026-08-10 | $3.58M 10-K · filed 2026-03-03 |
| 2025-09-30 | $846.00K 10-Q · filed 2025-11-06 | $1.76M derived: sum of 2 quarters · filed 2026-08-10 | $2.83M 10-Q · filed 2025-11-06 | $3.84M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $918.00K 10-Q · filed 2026-08-10 | $1.98M 10-Q · filed 2026-08-10 | $2.99M derived: sum of 3 quarters · filed 2026-08-10 | $4.10M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.06M 10-Q · filed 2026-05-11 | $2.07M derived: sum of 2 quarters · filed 2026-05-11 | $3.18M derived: sum of 3 quarters · filed 2026-05-11 | $4.37M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.12M derived: sum of 2 quarters · filed 2026-03-03 | $3.31M derived: sum of 3 quarters · filed 2026-03-03 | $4.67M 10-K · filed 2026-03-03 |
| 2024-09-30 | $1.11M 10-Q · filed 2025-11-06 | $2.30M derived: sum of 2 quarters · filed 2025-11-06 | $3.66M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.19M 10-Q · filed 2025-08-11 | $2.55M 10-Q · filed 2025-08-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $512.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $512.00K 10-Q · filed 2022-11-02 | $980.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $512.00K 10-Q · filed 2022-08-04 | $980.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.45M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $512.00K 10-Q · filed 2022-05-10 | $980.00K derived: sum of 2 quarters · filed 2023-03-16 | $1.45M derived: sum of 3 quarters · filed 2023-03-16 | $1.93M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $468.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $942.00K derived: sum of 2 quarters · filed 2023-03-16 | $1.42M derived: sum of 3 quarters · filed 2023-03-16 | $1.89M 10-K · filed 2023-03-16 |
| 2020-09-30 | $474.00K 10-Q · filed 2021-11-08 | $948.00K derived: sum of 2 quarters · filed 2021-11-08 | $1.42M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $474.00K 10-Q · filed 2021-08-04 | $944.00K 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $470.00K 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $3.71M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |